With its standing as Australia’s first locally grown medicinal cannabis producer, Little Green Pharma (LGP) has now become the first Australian company to export a locally grown medicinal cannabis product.
LGP has entered the highly lucrative German market, supplying samples of its commercial products 10:10 LGP Classic and 20:5 LGP classic to German cannabis distribution and wholesaler Cansativa GmbH for product testing. This comes after LGP received export licence approval in January.
Cansativa, a Frankfurt-based GDP-certified pharmaceutical wholesaler operating its own distribution and fulfillment centre, is one of the largest importers and distributors of medical cannabis in Germany.
Once product testing has been completed, the parties intend to finalise the supplier qualification for the European market and necessary compliance requirements.
“Being Australia’s first local producer of medicinal cannabis to have its products reach European soil is a major milestone in the company’s short history,” “Little Green Pharma Managing Director Fleta Solomon said.
“This partnership with Cansativa also highlights that our goal of bringing high-quality, cost-competitive Australian-produced medicinal cannabis to patients around the world has become a reality.
“We are thrilled to be working with a company of Cansativa’s standing, with this partnership just the beginning in LGP achieving its global export goal.”
Germany has become one of the fastest growing markets for medicinal cannabis in Europe since its legalisation in 2017. However, domestic cultivation has lagged due to delays in the tendering process which has resulted in product having to be imported in order to meet the increased demand and undersupply of medicinal cannabis to patients.
Cansativa is seeking to avoid supply bottlenecks becoming one of the largest importers and distributors of medicinal cannabis in Germany.